(Total Views: 443)
Posted On: 09/27/2025 1:38:50 PM
Post# of 157400
Re: KenChowder #157282
I totally agree. The fact that patients would not be able to receive an ICI for up to a year might even make many drop out of the trial.
This seems like the same old same old. Even beginning this protocol with a 350 mg dose delays a true assessment of the benefits that leronlimab might provide. Not making an ICI available to those who respond with elevating PD-L1 handicaps the trial and and is not in the best interest of the patients.
This seems like the same old same old. Even beginning this protocol with a 350 mg dose delays a true assessment of the benefits that leronlimab might provide. Not making an ICI available to those who respond with elevating PD-L1 handicaps the trial and and is not in the best interest of the patients.
(8)
(0)
